DDInter416 DDInter602
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dronedarone
Clotrimazole {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Dronedarone
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may lead to a major life threatening interaction when taken with {v} Dronedarone
Clotrimazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dofetilide
Dofetilide {u} (Compound) resembles {v} (Compound) Dronedarone
Clotrimazole {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Amiodarone
Amiodarone {u} (Compound) resembles {v} (Compound) Dronedarone
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronedarone
Clotrimazole {u} (Compound) resembles {v} (Compound) Loperamide
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibutilide
Ibutilide {u} (Compound) resembles {v} (Compound) Dronedarone
Clotrimazole {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronedarone
Clotrimazole {u} (Compound) causes {v} (Side Effect) Erythema
Erythema {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dronedarone
Clotrimazole {u} (Compound) resembles {v} (Compound) Diphenidol
Diphenidol {u} (Compound) resembles {v} (Compound) Fexofenadine
Fexofenadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronedarone
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Clotrimazole (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Dronedarone (Compound)
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may lead to a major life threatening interaction when taken with Dronedarone
Clotrimazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dofetilide (Compound) and Dofetilide (Compound) resembles Dronedarone (Compound)
Clotrimazole (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Amiodarone (Compound) and Amiodarone (Compound) resembles Dronedarone (Compound)
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clotrimazole (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Clotrimazole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Clotrimazole (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dronedarone
Clotrimazole (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone